Publicidad
Artículo original 01 de julio de 2011

Estudio biocinético y dosimétrico de un kit de producción local de 177Lu-EDTMP para su uso como agente paliativo del dolor

Referenciar Imprimir Descargar PDF

Referencias

  1. Begon F y Gaci M. Radionulide Therapy. Poitiers University Hospital. RGN International Edition. Vol A (6): 59-64, 1994.
  2. Pandit-Taskar N, Batraki M, Divgi C. Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases. J Nucl Med 2004;45: 1358-65.
  3. Bouchet L G, Bolch W E, Goddu S M, Howell R W, Rao D V. Considerations in the Selection of Radiopharmaceuticals for Palliation of Bone Pain from Metastatic Osseous Lesions. J Nucl Med 2000;41:682-7.
  4. De la Calle A B, González-González G, Fornés C, Martínez-Calderón F. 153Sm-EDTMP (Samario) como tratamiento del dolor óseo de origen metastático. Rev Soc Esp Dolor 2006;3:159-63.
  5. Crudo J, Nevares N. Radiopharmaceuticals labelled with Lu-177 for targeted therapy. En: Report of the Second Research Coordination Meeting on Development of therapeutic Radiopharmaceutical based on 177Lu for radionuclide therapy (2008, Milan, Italia) Reporte. Milán, Italia: European Institute of Oncology, 2008. pp 32-36.
  6. Das T, Chakraborty S, Unni PR, Banerjee S, Samuel G, Sarma H.D et al. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot 2002;57:177–84.
  7. Chakraborty S, Das T, Sarma H, Venkatesh M, Banerjee S. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot 2008;66:1196-205.
  8. Villarreal Y. Dosimetría Interna aplicada a Fármacos Marcados con 177Lu. Tesis (Maestría en Física Médica). Bariloche, Universidad Nacional de Cuyo, Instituto Balseiro, 2007. 145 p.
  9. Bayouth J, Macey D, Kasi L, Fossella F. Dosimetry and toxicity of Samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994;35:63-9.
  10. Eary J, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031-6.
  11. Galiano E, Stradiotto M. A statistical analysis of the initial biodistribution of 153Sm-EDTMP in a canine. Appl Radiat Isot 2005;63:79-85.
  12. ICRP 54. Individual Monitoring for Intakes of Radionuclides by Workers: Design and Interpretation, March, 1987.
  13. University of Washington. SAMM II User Guide Version 1.1.1. Seatlle, 2006.
  14. Snyder W, Ford M, Warner G, Watson SS. Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No 11. Society of Nuclear Medicine, Reston, VA, 1975.
  15. Loevinger R, Budinger T, Watson E. MIRD Primer for Absorbed Dose Calculations. Society of Nuclear Medicine. 1988.
  16. Larsson E, Strand S, Ljungberg M y Jönsson B. Mouse S-Factors based on Monte Carlo simulations in the anatomical realistic moby phantom for internal dosimetry. Cancer Biotherapy & Radiopharmaceuticals 2007;22: 438-42.
  17. Stabin M G. Fundamentals of Nuclear Medicine Dosimetry. Springer, 2008.
  18. Stabin M G, Sparks R B, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.
  19. Welch MJ, Redvanly CS. Handbook of radiopharmaceuticals. Radiochemistry and applications. New York: Wiley, 2003.
  20. Turner J, Claringbold P, Hetherington E, Sorby P, Martindale A. A Phase I clinical study of samarium-153-Ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989;7:1926-31.
  21. Collins C, Eary J, Donaldson G, Vernon C, Bush N, Petersdorf S et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A Phase I/II Trial. J Nucl Med 1993;34:1839-44.
  22. Resche I, Chatal J F, Pecking A, Eli P, Duchesne G, Rubens R et al. A Dose-controlled study of 153Sm-Ethylene-diamine-tetramethylene-phosphonate (EDTMP) in the treatment of patients with painful bone metastases. European Journal of Cancer 1997;33:1583-91.
  23. Alberts A, Smit B, Louw W, van Rensburg A, van Beek A, Kritzinger V, Nel J. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiotherapy and Oncology 1997;43:175-9.